Ken Griffin Sc Pharmaceuticals Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$4.12 - $5.51 $28,016 - $37,468	-6,800 Reduced 24.91%	20,500 $93,000
Q2 2024 Aug 14, 2024	SELL	$3.51 - $5.21 $31,589 - $46,890	-9,000 Reduced 24.79%	27,300 $118,000
Q1 2024 May 15, 2024	SELL	$4.86 - $6.39 $48,600 - $63,900	-10,000 Reduced 21.6%	36,300 $182,000
Q4 2023 Feb 14, 2024	BUY	$4.7 - $6.63 $39,480 - $55,692	8,400 Added 22.16%	46,300 $290,000
Q3 2023 Nov 14, 2023	SELL	$7.0 - $9.82 $140,700 - $197,382	-20,100 Reduced 34.66%	37,900 $269,000
Q2 2023 Aug 14, 2023	BUY	$8.94 - $11.74 $318,264 - $417,944	35,600 Added 158.93%	58,000 $591,000
Q1 2023 May 15, 2023	BUY	$5.59 - $9.47 $77,142 - $130,686	13,800 Added 160.47%	22,400 $203,000
Q4 2022 Feb 14, 2023	SELL	$4.02 - $7.53 $19,295 - $36,144	-4,800 Reduced 35.82%	8,600 $61,000
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.52 $60,032 - $87,368	13,400 New	13,400 $87,000

37.1M

110K

12.1K

Ticker SCPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,402,100
Market Cap $92.9M
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.